^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ixempra (ixabepilone)

    i
    Other names: BMS247550, NSC710428, NSC-710428, BMS 247550, azaepothilone B, epothilone B analogue, patupilone analogue, BMS-247550, NSC 710428
    Company:
    Allarity Therap, BMS, Otsuka, R-Pharm
    Drug class:
    Microtubule inhibitor
    Related drugs:
    Apply
    Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    09/14/2009
    Primary completion :
    01/31/2015
    Completion :
    03/06/2025
    AKT1
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • patupilone (EPO 906) • Vasforda (bevacizumab biosimilar)
    Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab (NCT03093155)
    Phase 2
    Yale University
    Completed
    Last update posted :
    05/14/2024
    Initiation :
    04/03/2017
    Primary completion :
    12/29/2022
    Completion :
    12/29/2022
    TUBB3
    |
    Avastin (bevacizumab) • Ixempra (ixabepilone)
    Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (NCT00877500)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    03/30/2009
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2
    |
    HER-2 negative
    |
    Ixempra (ixabepilone) • patupilone (EPO 906)
    Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (TavIx) (NCT00630032)
    Phase 3
    UNICANCER
    Completed
    Last update posted :
    02/21/2024
    Initiation :
    09/01/2007
    Primary completion :
    06/01/2017
    Completion :
    09/03/2020
    HER-2 • ER • PGR
    |
    HER-2 negative • HR negative • PGR negative
    |
    docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Ixempra (ixabepilone)
    Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA) (NCT06102824)
    Phase 2
    Guangdong Provincial People's Hospital
    Recruiting
    Last update posted :
    01/12/2024
    Initiation :
    01/20/2024
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    HER-2 • ER • PGR
    |
    HR positive • HER-2 negative • ER positive + PGR positive
    |
    carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • eribulin mesylate • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)
    A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN) (NCT02915744)
    Phase 3
    Nektar Therapeutics
    Completed
    Last update posted :
    04/14/2023
    Initiation :
    11/01/2016
    Primary completion :
    07/01/2020
    Completion :
    07/01/2020
    HER-2
    |
    gemcitabine • docetaxel • capecitabine • albumin-bound paclitaxel • irinotecan • eribulin mesylate • vinorelbine tartrate • Ixempra (ixabepilone) • Onzeald (etirinotecan pegol)
    PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (NCT02067416)
    Phase 2
    Jenny C. Chang, MD
    Withdrawn
    Last update posted :
    02/02/2023
    Initiation :
    07/01/2012
    Primary completion :
    06/01/2014
    Completion :
    06/01/2014
    HER-2
    |
    HER-2 negative
    |
    docetaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • epirubicin • Ixempra (ixabepilone)
    Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (CALGB 40502) (NCT00785291)
    Phase 3
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    10/13/2008
    Primary completion :
    12/31/2013
    Completion :
    06/15/2017
    ER • PGR
    |
    HER-2 overexpression • HER-2 negative
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • patupilone (EPO 906) • Vasforda (bevacizumab biosimilar)
    Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer (NCT00866905)
    Phase 2
    SCRI Development Innovations, LLC
    Completed
    Last update posted :
    11/22/2021
    Initiation :
    04/01/2009
    Primary completion :
    07/01/2014
    Completion :
    10/01/2014
    HER-2 • PGR
    |
    HER-2 negative
    |
    cyclophosphamide • Ixempra (ixabepilone) • cyclophosphamide intravenous
    Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer (NCT00207090)
    Phase 1
    R-Pharm
    Completed
    Last update posted :
    11/02/2020
    Initiation :
    09/01/2005
    Primary completion :
    11/01/2008
    Completion :
    11/01/2008
    CYP3A4
    |
    Ixempra (ixabepilone) • rifampicin
    Ixabepilone and SBRT For Metastatic Breast Cancer (NCT01818999)
    Phase 2
    University of Texas Southwestern Medical Center
    Withdrawn
    Last update posted :
    08/20/2020
    Initiation :
    08/01/2013
    Primary completion :
    04/01/2015
    Completion :
    04/01/2015
    HER-2
    |
    HER-2 negative
    |
    Ixempra (ixabepilone)